Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: MarcG who wrote (161)	10/26/1999 12:50:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 370

NEW YORK -- An offering of 2.2 million common shares of Vion Pharmaceuticals Inc. (VION) was priced at $5 each through underwriters led by Brean Murray & Co. The size of the offering was decreased from the originally planned 3.6 million shares. Gross spread is 35 cents, selling concession is 21 cents and no reallowance. Delivery is scheduled for Oct. 29. Proceeds from the offering are expected to be used for working capital, including product research and development, marketing and other general purposes. Jim